SCYNEXIS (SCYX) Expected to Announce Quarterly Earnings on Wednesday

SCYNEXIS (NASDAQ:SCYX) is expected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

SCYNEXIS (NASDAQ:SCYX) last posted its earnings results on Wednesday, March 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%. The firm had revenue of $0.98 million during the quarter.

SCYNEXIS Stock Performance

NASDAQ SCYX opened at $0.94 on Wednesday. The business has a 50 day simple moving average of $0.95 and a 200 day simple moving average of $1.11. SCYNEXIS has a 52-week low of $0.73 and a 52-week high of $3.07. The stock has a market cap of $36.69 million, a price-to-earnings ratio of -1.27 and a beta of 1.65.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on SCYNEXIS in a report on Thursday, May 1st. They set a “hold” rating for the company.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.